IDYA
IDEAYA Biosciences, Inc. NASDAQ Listed May 23, 2019$28.24
Pre-mkt
$28.39
+0.53%
Mkt Cap $2.5B
52w Low $16.84
50.8% of range
52w High $39.28
50d MA $31.92
200d MA $30.50
P/E (TTM)
-22.0x
EV/EBITDA
-19.2x
P/B
2.4x
Debt/Equity
0.0x
ROE
-11.1%
P/FCF
-41.6x
RSI (14)
—
ATR (14)
—
Beta
0.02
50d MA
$31.92
200d MA
$30.50
Avg Volume
1.2M
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
7000 Shoreline Court · South San Francisco, CA 94080 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 5, 2026 | TNS | -0.99 | -1.11 | -12.3% | 28.80 | -1.9% | -0.2% | -1.9% | — | — | — | — |
| Feb 17, 2026 | TNS | -0.95 | -0.94 | +1.2% | 30.76 | -0.7% | +0.5% | +7.0% | +4.0% | +4.4% | +4.3% | — |
| Nov 4, 2025 | TNS | -0.95 | 1.33 | +240.6% | 30.48 | +0.5% | -2.7% | -2.1% | -0.8% | +1.3% | +5.0% | — |
| Aug 5, 2025 | TNS | -0.85 | -0.88 | -3.5% | 24.12 | -0.5% | -2.0% | -7.1% | -4.2% | -5.3% | -2.2% | — |
| May 6, 2025 | TNS | -0.75 | -0.82 | -9.3% | 17.75 | +2.9% | +0.5% | +2.4% | -1.9% | +3.4% | -1.7% | — |
| Feb 13, 2025 | TNS | -0.67 | -1.49 | -122.4% | 20.76 | +0.6% | +1.2% | -1.5% | -0.5% | +4.7% | +5.3% | — |
| Nov 4, 2024 | TNS | -0.67 | -0.60 | +10.4% | 30.00 | -2.1% | -1.4% | +1.4% | -0.0% | +4.3% | +6.6% | — |
| Aug 6, 2024 | TNS | -0.55 | -0.68 | -23.6% | 36.00 | +0.6% | -0.4% | +4.4% | +5.2% | +4.4% | +6.1% | — |
| May 7, 2024 | TNS | -0.53 | -0.53 | +0.0% | 42.75 | -2.2% | -3.1% | -4.9% | -3.7% | -3.9% | -2.2% | — |
| Feb 20, 2024 | TNS | -0.49 | -0.52 | -6.1% | 44.01 | +1.1% | +0.6% | +1.2% | +4.2% | +4.9% | +3.2% | — |
| Nov 7, 2023 | TNS | -0.47 | -0.46 | +2.1% | 29.26 | +0.5% | +5.7% | +0.4% | +0.4% | -0.2% | +1.8% | — |
| Aug 10, 2023 | TNS | -0.53 | -0.50 | +5.7% | 25.50 | +1.4% | -1.5% | -2.9% | +0.5% | -0.9% | -2.5% | — |
| May 9, 2023 | AMC | -0.51 | -0.49 | +3.9% | 22.26 | +1.6% | +0.8% | -3.7% | -3.9% | -2.7% | -4.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 14 | Wells Fargo | Maintains | Overweight → Overweight | — | $32.82 | $33.37 | +1.7% | -1.4% | -1.9% | -0.9% | +3.3% | +2.4% |
| Apr 14 | Guggenheim | Maintains | Buy → Buy | — | $32.82 | $33.37 | +1.7% | -1.4% | -1.9% | -0.9% | +3.3% | +2.4% |
| Apr 14 | Goldman Sachs | Maintains | Neutral → Neutral | — | $32.82 | $33.37 | +1.7% | -1.4% | -1.9% | -0.9% | +3.3% | +2.4% |
| Apr 14 | RBC Capital | Maintains | Outperform → Outperform | — | $32.82 | $33.37 | +1.7% | -1.4% | -1.9% | -0.9% | +3.3% | +2.4% |
| Apr 14 | Wedbush | Maintains | Outperform → Outperform | — | $32.82 | $33.37 | +1.7% | -1.4% | -1.9% | -0.9% | +3.3% | +2.4% |
| Mar 31 | Wedbush | Maintains | Outperform → Outperform | — | $31.45 | $32.06 | +1.9% | +5.9% | +3.3% | +4.1% | +2.8% | -1.7% |
| Feb 19 | Citigroup | Maintains | Buy → Buy | — | $30.92 | $31.06 | +0.5% | +6.4% | +3.4% | +3.8% | +3.7% | +2.4% |
| Feb 18 | Wedbush | Maintains | Outperform → Outperform | — | $30.76 | $30.55 | -0.7% | +0.5% | +7.0% | +4.0% | +4.4% | +4.3% |
| Feb 18 | Guggenheim | Maintains | Buy → Buy | — | $30.76 | $30.55 | -0.7% | +0.5% | +7.0% | +4.0% | +4.4% | +4.3% |
| Feb 18 | RBC Capital | Maintains | Outperform → Outperform | — | $30.76 | $30.55 | -0.7% | +0.5% | +7.0% | +4.0% | +4.4% | +4.3% |
| Jan 21 | RBC Capital | Maintains | Outperform → Outperform | — | $35.75 | $36.01 | +0.7% | +0.7% | +1.3% | -2.7% | -3.6% | -2.8% |
| Jan 6 | Truist | Maintains | Buy → Buy | — | $34.94 | $34.85 | -0.3% | +3.9% | +8.4% | +4.3% | +7.0% | +5.4% |
| Nov 11 | Mizuho | Maintains | Outperform → Outperform | — | $30.89 | $30.86 | -0.1% | +3.6% | +3.4% | +3.0% | +4.0% | +7.9% |
| Oct 23 | JP Morgan | Maintains | Overweight → Overweight | — | $28.64 | $28.88 | +0.8% | -0.8% | +1.9% | +13.0% | +15.9% | +12.4% |
| Oct 21 | RBC Capital | Maintains | Outperform → Outperform | — | $30.51 | $30.52 | +0.0% | -4.3% | -6.1% | -6.9% | -4.4% | +6.1% |
| Oct 21 | Goldman Sachs | Maintains | Neutral → Neutral | — | $30.51 | $30.52 | +0.0% | -4.3% | -6.1% | -6.9% | -4.4% | +6.1% |
| Oct 21 | BTIG | Maintains | Buy → Buy | — | $30.51 | $30.52 | +0.0% | -4.3% | -6.1% | -6.9% | -4.4% | +6.1% |
| Sep 12 | Mizuho | Maintains | Outperform → Outperform | — | $24.93 | $24.94 | +0.0% | -1.3% | -1.6% | -0.8% | -2.0% | +5.2% |
| Sep 9 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $23.39 | $24.06 | +2.9% | +5.8% | +5.6% | +6.6% | +5.2% | +4.9% |
| Sep 9 | Stephens & Co. | Maintains | Overweight → Overweight | — | $23.39 | $24.06 | +2.9% | +5.8% | +5.6% | +6.6% | +5.2% | +4.9% |
| Sep 9 | RBC Capital | Maintains | Outperform → Outperform | — | $23.39 | $24.06 | +2.9% | +5.8% | +5.6% | +6.6% | +5.2% | +4.9% |
| Sep 8 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $27.16 | $27.69 | +2.0% | -13.9% | -8.9% | -9.0% | -8.2% | -9.4% |
| Sep 3 | JP Morgan | Maintains | Overweight → Overweight | — | $25.48 | $25.50 | +0.1% | +1.1% | +1.4% | +6.6% | -8.2% | -2.9% |
| Jul 28 | JP Morgan | Maintains | Overweight → Overweight | — | $24.50 | $25.18 | +2.8% | +2.1% | +1.4% | +3.5% | -0.6% | -0.9% |
| Jul 9 | RBC Capital | Maintains | Outperform → Outperform | — | $21.45 | $21.70 | +1.2% | +7.1% | +6.3% | +4.8% | +5.3% | -0.1% |
| May 22 | JP Morgan | Maintains | Overweight → Overweight | — | $19.15 | $19.09 | -0.3% | -2.5% | -1.7% | +1.4% | +2.1% | +4.7% |
| Feb 14 | Stephens & Co. | Maintains | Overweight → Overweight | — | $20.76 | $20.89 | +0.6% | +1.2% | -1.5% | -0.5% | +4.7% | +5.3% |
| Jan 15 | RBC Capital | Maintains | Outperform → Outperform | — | $22.74 | $23.37 | +2.8% | +2.3% | -0.1% | -2.5% | +1.8% | +1.8% |
| Jan 13 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $24.03 | $23.82 | -0.9% | -4.4% | -5.4% | -3.2% | -5.5% | -7.7% |
| Dec 17 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $26.05 | $25.89 | -0.6% | +1.1% | -1.8% | -4.8% | -1.7% | -2.6% |
| Dec 17 | Wedbush | Maintains | Outperform → Outperform | — | $26.05 | $25.89 | -0.6% | +1.1% | -1.8% | -4.8% | -1.7% | -2.6% |
| Nov 5 | Leerink Partners | Downgrade | Outperform → Market Perform | — | $30.00 | $29.36 | -2.1% | -1.4% | +1.4% | -0.0% | +4.3% | +6.6% |
| Oct 29 | Oppenheimer | Maintains | Outperform → Outperform | — | $30.01 | $29.72 | -1.0% | -0.5% | -1.8% | -6.2% | -4.7% | -0.0% |
| Sep 24 | RBC Capital | Maintains | Outperform → Outperform | — | $33.73 | $33.85 | +0.4% | -7.0% | -10.0% | -9.6% | -8.7% | -6.1% |
| Sep 24 | Wedbush | Maintains | Outperform → Outperform | — | $33.73 | $33.85 | +0.4% | -7.0% | -10.0% | -9.6% | -8.7% | -6.1% |
| Sep 10 | Stifel | Maintains | Buy → Buy | — | $36.45 | $36.82 | +1.0% | +0.5% | -0.7% | -0.9% | +2.8% | +1.0% |
| Aug 27 | Citigroup | Maintains | Buy → Buy | — | $39.80 | $39.44 | -0.9% | -1.1% | -0.5% | -1.6% | -0.8% | -4.2% |
| Aug 8 | JP Morgan | Maintains | Overweight → Overweight | — | $35.86 | $36.03 | +0.5% | +4.8% | +5.7% | +4.8% | +6.5% | +2.5% |
| Aug 7 | Oppenheimer | Maintains | Outperform → Outperform | — | $36.00 | $36.22 | +0.6% | -0.4% | +4.4% | +5.2% | +4.4% | +6.1% |
| Aug 7 | RBC Capital | Maintains | Outperform → Outperform | — | $36.00 | $36.22 | +0.6% | -0.4% | +4.4% | +5.2% | +4.4% | +6.1% |
| Aug 7 | Wedbush | Maintains | Outperform → Outperform | — | $36.00 | $36.22 | +0.6% | -0.4% | +4.4% | +5.2% | +4.4% | +6.1% |
| Jul 12 | JP Morgan | Maintains | Overweight → Overweight | — | $39.62 | $40.30 | +1.7% | +1.0% | +4.4% | +7.6% | +2.8% | +3.8% |
| Jul 11 | RBC Capital | Maintains | Outperform → Outperform | — | $37.32 | $38.68 | +3.6% | +6.2% | +7.2% | +10.8% | +14.3% | +9.1% |
| Jul 9 | BTIG | Maintains | Buy → Buy | — | $39.51 | $39.93 | +1.1% | -2.3% | -5.5% | +0.3% | +1.2% | +4.7% |
| Jul 8 | Oppenheimer | Maintains | Outperform → Outperform | — | $34.26 | $39.28 | +14.7% | +15.3% | +12.7% | +8.9% | +15.6% | +16.8% |
| Jul 8 | Stifel | Maintains | Buy → Buy | — | $34.26 | $39.28 | +14.7% | +15.3% | +12.7% | +8.9% | +15.6% | +16.8% |
| Jun 4 | Stifel | Maintains | Buy → Buy | — | $38.89 | $39.47 | +1.5% | -0.7% | +2.0% | +1.9% | -2.3% | -1.4% |
| May 13 | Goldman Sachs | Maintains | Buy → Buy | — | $41.17 | $41.45 | +0.7% | -0.2% | +1.5% | +3.1% | +0.9% | -1.6% |
| May 8 | Wedbush | Maintains | Outperform → Outperform | — | $42.75 | $41.81 | -2.2% | -3.1% | -4.9% | -3.7% | -3.9% | -2.2% |
| Mar 21 | Citigroup | Maintains | Buy → Buy | — | $44.81 | $45.84 | +2.3% | +1.8% | -4.0% | -5.6% | -5.1% | -3.3% |
No insider trades available.
8-K · 2.02
!! High
IDEAYA Biosciences, Inc. -- 8-K 2.02: Earnings Results
IDEAYA Biosciences reported financial results and operational updates via press release, with details available in the attached exhibit for investor review of company performance.
May 5
8-K
Unknown — 8-K Filing
Idya Pharmaceuticals' darovasertib combination demonstrated compelling efficacy in an NDA submission with 58% risk reduction in disease progression, potentially supporting regulatory approval and significant commercial value creation.
Apr 13
8-K
Unknown — 8-K Filing
This boilerplate safe harbor language is standard legal protection; it doesn't signal material news, so investors should focus on the actual 8-K disclosures rather than this disclaimer alone.
Apr 9
8-K
IDEAYA Biosciences, Inc. -- 8-K Filing
IDEAYA Biosciences delivered strong fourth-quarter 2025 execution with clinical progress and pipeline expansion, positioning the precision oncology company for potential commercial momentum ahead.
Feb 17
Data updated apr 25, 2026 2:59pm
· Source: massive.com